CHRISTOPHER BUNKA - 12 Oct 2022 Form 4/A - Amendment Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Chief Executive Officer, Director
Signature
/Chris Bunka/
Issuer symbol
LEXX
Transactions as of
12 Oct 2022
Net transactions value
+$78,397
Form type
4/A - Amendment
Filing time
18 Oct 2022, 18:20:31 UTC
Date Of Original Report
13 Oct 2022
Previous filing
29 Aug 2022
Next filing
30 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX common shares Purchase $43,537 +21,900 +10% $1.99 237,812 12 Oct 2022 Private Holding Company F1
transaction LEXX common shares Purchase $34,860 +16,600 +7% $2.10 254,412 13 Oct 2022 Private Holding Company F1
holding LEXX common shares 273,543 12 Oct 2022 Direct
holding LEXX common shares 215,912 12 Oct 2022 Private Holding Company
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4/A is being filed to correct the transaction code for the open market purchase of common shares made by Mr. Bunka as previously notated as a grant or award in the Form 4 originally filed on 10/13/2022.